PROCEPT BioRobotics (PRCT) Expected to Release Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to be posting its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect PROCEPT BioRobotics to announce earnings of ($0.46) per share and revenue of $92.7710 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

PROCEPT BioRobotics Price Performance

PRCT opened at $18.62 on Monday. PROCEPT BioRobotics has a 12 month low of $16.67 and a 12 month high of $51.38. The business has a 50-day moving average of $22.39 and a two-hundred day moving average of $25.15. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -10.23 and a beta of 0.89.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of large investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in PROCEPT BioRobotics during the 4th quarter worth approximately $469,000. T. Rowe Price Investment Management Inc. lifted its position in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares in the last quarter. Invesco Ltd. boosted its stake in shares of PROCEPT BioRobotics by 19.8% in the fourth quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock valued at $1,371,000 after purchasing an additional 7,191 shares during the period. EP Wealth Advisors LLC acquired a new stake in PROCEPT BioRobotics during the 4th quarter valued at $300,000. Finally, Mackenzie Financial Corp grew its holdings in PROCEPT BioRobotics by 8.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after purchasing an additional 118,971 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

Wall Street Analysts Forecast Growth

PRCT has been the subject of several research analyst reports. Truist Financial reaffirmed a “hold” rating and set a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a research report on Thursday, July 2nd. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. UBS Group downgraded PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a report on Tuesday, July 28th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $33.45.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.